Systemic Antimicrobials Consumption and Expenditures in Intensive Care Units of Hospitals in Russian Federation and Republic of Belarus: Results of Multicenter Pharmacoepidemiological Study

Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(4):294-311

Type
Journal article

Abstract

To assess systemic antimicrobials (AM) consumption and expenditures in intensive care units (ICU) of multiprofile hospitals in different regions of Russian Federation and Republic of Belarus in 2009–2010 retrospective collection of data from hospital expenditure notes was performed. AM consumption was calculated using ATC/DDD methodology and expressed in numbers of DDD/100 bed-days (DBD). Average AM consumption and expenditure rates in ICU in 2009 and 2010 were as follows: 122.5 DBD / 2.1 million rubles and 133.8 DBD / 2.4 million rubles; average cost of 1 DDD — 444.1 and 459.8 rubles, respectively. The highest consumption rates were for antibacterials for systemic use, J01 (97.6% in 2009 and 98.1% in 2010), such as non-penicillin beta-lactams, J01D (62.8% and 56.4%), other antibacterials, J01X, (12.4% and 13.6%, respectively), as well as quinolones, J01M, (12.4% in 2009) and aminoglycoside antibacterials, J01G, (10% in 2010); the highest expenditure rates — for antibacterials for systemic use, J01 (97.9% in 2009 and 98.4% in 2010), such as non-penicillin beta-lactams, J01D, (72.4% and 67.7%), other antibacterials, J01X, (13.9% and 8.5%, respectively), as well as quinolones, J01M, (6.7% in 2009) and aminoglycoside antibacterials, J01G, (7.7% in 2010). Improper AM consumption rates were unreasonably high (12.2% in 2009 and 11.1% in 2010) whereas improper expenditure rates were relatively low (2% and 1.4%, respectively). Study outputs can be used for budget allocation and AM distribution improvement in ICU as well as for development and efficacy control of local antimicrobial stewardship programs.

Views
0 Abstract
0 PDF
0 BibTeX
Shared
0
0
0
0
0
0